Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 19 to 55 years of age~* Written informed consent~* Available for all visits and telephone calls scheduled for the study~Exclusion Criteria:~* Previous or suspected disease caused by N. meningitides~* Household and/or intimate exposure to an individual with culture-proven N. meningitides infection within 60 days prior to screening~* Serious acute, chronic or progressive disease as determined by investigator~* History of alcohol or substance abuse

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- EuNmCV-5 (Type: EXPERIMENTAL): Healthy adults received 0.5mL single intramuscular dose on Day 0.
- Menveo (Type: ACTIVE_COMPARATOR): Healthy adults received 0.5mL single intramuscular dose on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).